Necrosis News and Research

RSS

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

The therapeutic effects of tumor necrosis factor-α inhibitors in psoriasis occur through a reduction in the antioxidant response of mesenchymal stem cells, suggest study findings.

15 Jun 2012

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Patients with inflammatory rheumatic diseases who are treated with anti-tumor necrosis factor medications are significantly more likely to experience herpes zoster infections than those treated with traditional disease-modifying anti-rheumatic drugs, study results show.

15 Jun 2012

Rheumatism drugs may increase shingles risk

Patients with inflammatory rheumatic disease treated with one of the most effective medicines for their disease face a substantially increased risk for developing shingles, warn European researchers who suggest vaccination may be an option.

15 Jun 2012

Rheumatoid arthritis infection risk predicted by RABBIT

The RABBIT risk score can predict the likelihood of serious infection in rheumatoid arthritis patients using tumor necrosis factor-alpha inhibitors and disease-modifying antirheumatic drugs, research confirms.

11 Jun 2012

Rheumatoid arthritis drug has added benefits

Treatment with anti-tumor necrosis factor drugs reduces the risk for cardiovascular events in patients with rheumatoid arthritis, researchers report.

8 Jun 2012

Smoking RA patients don't respond to anti-TNF drugs

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

8 Jun 2012

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.

8 Jun 2012

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics. Since the inception of this MMRF program in 2006, $11.5 million has been committed to 12 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

8 Jun 2012

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.

8 Jun 2012

Biologic treatments reduce mortality risk in patients with rheumatoid arthritis

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).

7 Jun 2012

English Rheumatoid Arthritis care standards out of step with Europe

A 12-country comparative analysis of rheumatoid arthritis (RA) treatment guidelines reveals that there is considerable variation in patient access to care, with England out of step with standards adopted by its European counterparts.

6 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

Hip arthroplasty pseudotumors ‘cause for great concern’

Pseudotumors may be 10 times more common in patients after metal-on-metal hip resurfacing and total hip replacement than thought, suggest Dutch researchers.

1 Jun 2012

Functional disability impacts educational attainment in children with JIA

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

1 Jun 2012

Thrombosis biomarker levels differ according to thrombolysis strategy

An early invasive strategy following thrombolysis for ST-segment-elevation myocardial infarction is associated with significant changes in the levels of inflammatory and thrombotic biomarkers, a substudy of the Norwegian study on district treatment of STEMI shows.

31 May 2012

Juvenile Arthritis patients may have difficulties achieving educational success

31 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012